Literature DB >> 20546884

Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures.

Raghunandan Dudda Subramanya1, Alvin B Coda, Animesh A Sinha.   

Abstract

Alopecia areata (AA) is a non-scarring inflammatory hair loss disease with a complex autoimmune etiopathogenesis that is poorly understood. In order to investigate the pathogenesis of AA at the molecular level, we examined the gene expression profiles in skin samples from lesional (n=10) and non-lesional sites (n=10) of AA patients using Affymetrix Hu95A-v2 arrays. 363 genes were found to be differentially expressed in AA skin compared to non-lesional skin; 97 were up-regulated and 266 were down-regulated. Functional classification of the differentially expressed genes (DEGs) provides evidence for T-cell mediated immune response (CCL5, CXCL10, CD27, ICAM2, ICAM3, IL7R, and CX3CL1), and a possible humoral mechanism (IGHG3, IGHM, and CXCR5) in AA. We also find modulation in gene expression favoring cellular proliferation arrest at various levels (FGF5, FGF18, EREG, and FOXC2) with apoptotic dysregulation (LCK, TNF, TRAF2, and SFN) and decreased expression of hair follicle structural proteins. Further analysis of patients with AAT (<1 year duration, n=4) and AAP (>1 year duration, n=6) of disease revealed 262 DEGs distinctly separating the 2 groups, indicating the existence of gene profiles unique to the initial and later stages of disease.

Entities:  

Mesh:

Year:  2010        PMID: 20546884     DOI: 10.1016/j.ygeno.2010.05.002

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  18 in total

Review 1.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 2.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

3.  IL12B and IL23R polymorphisms are associated with alopecia areata.

Authors:  Pardis-Sadat Tabatabaei-Panah; Hamideh Moravvej; Sara Delpasand; Mona Jafari; Sanaz Sepehri; Reyhaneh Abgoon; Ralf J Ludwig; Reza Akbarzadeh
Journal:  Genes Immun       Date:  2020-05-01       Impact factor: 2.676

Review 4.  The genetics of human skin disease.

Authors:  Gina M DeStefano; Angela M Christiano
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

5.  Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer.

Authors:  Chao Yang; Xiaoxian Cui; Xiaoqin Dai; Wenting Liao
Journal:  Oncol Lett       Date:  2016-01-08       Impact factor: 2.967

Review 6.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

7.  The Concept of Immunogenetics.

Authors:  Fateme Rajabi; Navid Jabalameli; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

8.  The Immunogenetics of Alopecia areata.

Authors:  Fateme Rajabi; Fahimeh Abdollahimajd; Navid Jabalameli; Mansour Nassiri Kashani; Alireza Firooz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

9.  Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection.

Authors:  Arzu Cakir; Melisa Tuncer; Hilal Taymaz-Nikerel; Ozlem Ulucan
Journal:  Pharmacogenomics J       Date:  2021-06-21       Impact factor: 3.550

10.  Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse.

Authors:  Caroline G McPhee; F Jason Duncan; Kathleen A Silva; Lloyd E King; Harm Hogenesch; Derry C Roopenian; Helen B Everts; John P Sundberg
Journal:  J Invest Dermatol       Date:  2012-02-23       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.